pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN® in Diabetic Macular Edema
"This is an unprecedented product," said Navid Malik, an analyst at Collins Stewart. "The whole field has opened up with this vaccine."
Though the vaccine has only been approved in Switzerland, patients from all over Europe are likely to travel for treatment, Malik said.
The product combines the patient's immune cells with so-called cancer biomarkers from the tumor and injects the solution into the patient, the company said in the statement. DCVax-Brain allows the immune system to fight the disease without side effects. Studies found the medicine delays recurrence of the tumor by 18.1 months for new patients, Northwest said.
Malik upgraded his 2009 sales forecasts to $36 million from $15 million and net income to $11.5 million from $3.3 million.
He has a "strong buy" rating on the shares.
"I believe this will become the standard of care globally," Malik said.
According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30 percent.
The implied treatment costs would be $75,000 per
patient for a 3 year supply
Collins Stewart analyst Navid Malik estimates that the product will generate $15m (�11m) next year
(treating just 200 patients)
so - if I use my calculator correctly that works out to
15,000,000 / 200 = $75,000 per patient vaccine cost
which means a net profit for NWBT of $3.3m, while revenues for 2009 are expected to reach $36m with a $11.5m net profit for the company.
its a Coal thingie that may have fell into
Read Silicon Investor, StockHouse, etc.
They are supposed to be out with a News
Release before the 31st.
Today they caught everyone off guard and
said they are putting more drills in.
(Can be read either way)
The same SI crowd that was all over ARU
*before* ARU went nuts, is pounding the
table about this one.
They are JV with TSC (?).
Even the coal alone may be cool because
they are gonna try and do - Coal to Liquification ??? with China. Thats a guess
NOT a fact.
I am in for a bunch.
don't bother to reply because I will never
find your post.
Bumped into this on SI and thought I'd
pass it along here ....
Hope the CROW is all cooked.
The Chief Financial Officer of NTII quit.
Usually, (70% of the time) that spells trouble.
However - NOT IN THIS CASE.
Whats going on?
(a) I don't know.
(b) Betcha dollar to donuts the guy wanted
MORE STAFF and he couldn't get it.
(c) How do I know this?
I really DON'T know this but I DO KNOW
The guy is probably working 80 hrs a week
now and said screw-it. Moneywise its better
to be a consultant because at least they
gotta pay me on a per hour basis.
(The guy is staying on as a consultant)
(d) Whoever Paul hires watch and I would
bet that that person will get additional
staff - hopefully at least 2 more and
preferably 3 more people.
(e) If Paul would HUMP THE BOOKS for a couple
of months he'd sort get an education he
missed somewhere along the way.
(f) Again, I could be ALL WET but I kindda
was wondering about this way back when.
Note:I also bettcha the NEXT guy is UNDER
In any event, its June, and if we can
crawl our way thru to the middle of Sept
then I suspect all SAFETY ISSUES are off
the table and this drug will just boil
down to efficacy.
will see you in two weeks ...
(I got xxx email about the earthquake)
I didn't know what the heck was going on
and (stupid me) couldn't figure out how
it didn't hurt any humans in trials
but COR was forced to go backwards.
IOW - I got scared.
great info ...
I like your title "Shine is dimming"
Here's a piece on WHY.
Gold bullion prices have fallen by more than 10% in the past month, even, as BCA Research puts it �as investor concerns about inflation have escalated.� Gold bullion is normally seen as a hedge against inflation; this time around, far from this theme not working out, the inverse has occurred. Analysts at BCA Research argue that investors� recent counter-intuitive reaction underscores the fact that the earlier rally in gold bullion reflected to a large extent a liquidity boom that investors now fear is being unwound.
The above is in context but the article's
scope is wider than above.
SI went nuts about ARU.V ..... the leader
of the pack on SI pounding the table
was a guy called Red Rocket ....
now here is the rest of the story and this
is simply a CRAP SHOOT ....
there are two more explorers right next to
SI seems to favor ORR.V more than GML.V
but nobody knows for sure. Again, this is
strictly in the CRAP SHOOT category.
At the top in the SEARCH BOX type in
... AND ... chenge the dropdown next
to it to PUBLIC MESSAGES.
Then hit the SEARCH BUTTON.
From: allevett 6/10/2006 4:36:04 PM
Published on Sunday, June 11, 2006 by ASPO
Canada�s oil sands will not prevent Peak Oil
If I read this right - we can't find/build
enough oil fast enough.
When you find the one you love (oil stock)
(and maybe you have already) please yell
follow this guy (good poster)
SI loves this stock ...
MMGG has the ZN/AU equiv of 11 mill ounces of AU. 1.5 to 2 bil value. 50 million shares. 30 bucks a share on TO. Could happen.Does not take into account the price increase of zinc nor the silver side which is coming up roses.
ARU may well go over 30 bucks but hard to jump on a train moving that fast.
I ain't in it ... and wish I was.
1: Prog Neuropsychopharmacol Biol Psychiatry. 2006 May 25; [Epub ahead of print] Related Articles, Links
Memantine augmentation for refractory obsessive-compulsive disorder.
Pasquini M, Biondi M.
Department of Psychiatric Science and Psychological Medicine, University "La Sapienza" of Rome, Italy.
Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested.
Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist.
We report two cases of refractory obsessive-compulsive disorder treated with an augmentation of memantine at 15 mg/day.
The first case did not benefit from such treatment,
while the second showed ***immediate and substantial*** improvement.
Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation.
just saw this ...
As is also the case with any therapeutic category of this size 'in the making,' there will be no shortage of competitors lining up to challenge Provigil -- once they have traversed the clinical and regulatory minefields that lie before commercialization. The most promising next-generation drug is Cortex's (AMEX:COR - News) CX717, which has shown well in clinical testing thus far, with another DARPA study due to report this month. CX717 is early in development, and even when its current clinical hold is lifted in early fall, as we expect, it still will have to be brought through pivotal trials by whichever major pharmaceutical company licenses it by year-end. Abbott, Hypnion, Arena Pharmaceuticals, and Vanda Pharmaceuticals are also active in this field, and we expect many more to enter as the commercial viability of the area becomes established.
then go forward and backward from the link
I thought the FDA is making them redo some
stuff or resubmit some stuff based on
animal trials from years ago - maybe I got
it wrong ...
ain't the FDA talking to them about prior
there are 2 trials ....
i've seen upwards of 50+ locations listed in the past
you are obviously citing the first trial ...
and I am talking about the 2nd trial ....
And - both trials have to be completed and
successful - for FDA approval .....
finally, you ALREADY know this ....
give it a break ....
I have not listened to call and do not
On the one hand the increase of the royalty
rate to 1.5% from 1.0% - on the face of it -
On the other hand - if they (John Hopkins)
would just get off its ass and START the
dementia LUPUS trials AND the OCD trials
come in favorably - then the 1/2% is gonna
Potentially, we could get more Lupus dementia
users than the current AD users.
I do not have a handle on the OCD population
As far as I know - DN and therefore the
13% is DEAD.